Semaglutide 7.2 mg Reports 20.7%: What STEP UP Means for the Tirzepatide Premium

What was reported

These are separate trials with different populations and durations. Only SURMOUNT-5 compared two of these drugs directly.

Why this reframes the head-to-head narrative

SURMOUNT-5 is routinely summarised as demonstrating that tirzepatide's dual GIP/GLP-1 mechanism is superior to GLP-1 alone. That reading has always carried a caveat: the trial compared each drug at its approved maximum, and those maxima were set by separate development programmes rather than by any principle of equivalence.

If semaglutide at 7.2 mg approaches tirzepatide's result, the mechanism argument weakens and a dose argument strengthens. The observed difference may reflect how much drug each product delivers at its approved ceiling rather than something intrinsic about acting on two receptors instead of one.

The question the trial exists to answer

Gastrointestinal adverse effects in this class are dose-related, and they are the primary driver of discontinuation. In SURMOUNT-1, 4.3% to 7.1% of participants discontinued because of an adverse event depending on dose.

A dose that produces more weight loss and more discontinuation may deliver less benefit in practice than a lower dose people stay on. That is why the treatment-policy estimand — which includes everyone regardless of adherence — matters more at higher doses than at lower ones.

We have not seen tolerability and discontinuation data for 7.2 mg. A weight-loss number without its discontinuation rate is half a result.

What approval would change about price

Tirzepatide is priced above semaglutide almost universally, and the efficacy gap is the justification.

If the efficacy gap narrows, this premium becomes harder to justify.

Status, stated plainly

Semaglutide 7.2 mg is not approved. It is not available from any provider, and it cannot lawfully be compounded — compounding a copy of an available approved product is generally not permitted, and this is not an approved product at all.

Where this sits in the 2026 pipeline

Every advance in this field for three years has come from adding mechanisms or raising doses. Semaglutide acts on GLP-1. Tirzepatide adds GIP and outperformed it head-to-head. Retatrutide adds glucagon. CagriSema adds amylin through a different hormone entirely. STEP UP takes the other route: more of an established mechanism rather than a new one.

That is a cheaper path to market. A higher-dose formulation of an approved molecule carries a known safety profile, established manufacturing and an existing prescriber base. It does not need to prove a new mechanism — only that the additional exposure is tolerable.

Why the estimand matters more at higher doses

Trials in this field publish more than one analysis. The treatment-regimen or treatment-policy estimand includes every randomised participant regardless of whether they kept taking the drug. The efficacy estimand estimates the effect assuming continued treatment.

SURMOUNT-1 published both: 15.0%, 19.5% and 20.9% on the treatment-regimen analysis, and 16.0%, 21.4% and 22.5% on the efficacy analysis. Marketing generally quotes the higher set without saying which produced it.

At a dose three times the approved maximum, that distinction stops being academic. If more people stop, the two estimands diverge further, and a headline figure drawn from the efficacy analysis describes a population that stayed on a drug many did not tolerate.

What this means if you are choosing now

A pipeline is not a treatment. If treatment is clinically indicated, waiting for an unapproved formulation has real costs — untreated time is not neutral.

What the pipeline does argue for is avoiding long commitments. The approved landscape has changed materially twice within eighteen months: two oral products reached market and brand prices fell sharply. A twelve-month prepayment made today forecloses a market still in motion, which is one reason month-to-month pricing is worth its premium for anyone not yet established on treatment.

What we are watching

Publication of STEP UP with tolerability and discontinuation data alongside the efficacy figure. Any regulatory submission for the 7.2 mg formulation. And whether the tirzepatide price premium moves in response — which would be the clearest signal that the market believes the efficacy gap has narrowed.

What the dose-response data already told us

SURMOUNT-1 reported mean weight reduction rising from about 15.0% at 5 mg to 19.5% at 10 mg and 20.9% at 15 mg. The relationship is clean and monotonic: more dose, more effect, across the studied range.

Semaglutide's approved weight-management maximum of 2.4 mg was set by its own development programme, not by any finding that higher doses stop working. STEP UP tests the obvious question that raises — whether the ceiling was a development decision rather than a pharmacological limit.

If the answer is that it was a development decision, then a substantial part of what the field has interpreted as a mechanism difference between the two molecules may be a dosing difference. That would not make SURMOUNT-5 wrong. It would make its result a comparison of two products at their respective approved ceilings, which is what it always literally was.

What approval would mean for patients on semaglutide now

For someone tolerating semaglutide well but plateauing below their target, a higher-dose option within a familiar molecule and a known safety profile is genuinely useful. Switching molecules means restarting titration, and tolerability does not transfer — a patient who does well on one may not on the other.

For someone already struggling with gastrointestinal effects at 2.4 mg, it changes nothing. Dose-related adverse effects are the constraint that defines this class, and a higher dose does not help a patient who cannot reach the current one.

What it would not do is arrive cheaply. New formulations launch at brand pricing, and coverage takes quarters rather than weeks to establish. The Wegovy pill and Foundayo are the useful precedents: both launched from $149 with savings programmes bringing eligible commercially insured patients to around $25, but neither was cheap for everyone on day one.